Current NCCN Guideline recommendations for metastatic HR+/HER2−, breast cancer include the addition of CDK4/6Is with hormonal therapy (letrozole, fulvestrant) in postmenopausal and for premenopausal patients as a preferred first-line treatment (Table 1, [33]). The gene discussed is CDK4; the disease is breast carcinoma.